A New Hope for Melanoma, But Whose Hope?
The recent announcement from Moderna and Merck about their mRNA based vaccine's success in a Phase 3 trial of melanoma patients is being hailed as a breakthrough in cancer therapy.
This development holds promise for those affected by the deadliest form of skin cancer, but it also raises questions about access, equity, and the long term implications of personalized medicine.